Crossmark

Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)

Crossref DOI link: https://doi.org/10.1007/s00277-023-05168-8

Published Online: 2023-03-13

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Breccia, Massimo https://orcid.org/0000-0003-1163-6162
Olimpieri, Pier Paolo

Celant, Simone

Olimpieri, Odoardo Maria

Pane, Fabrizio

Iurlo, Alessandra

Summa, Valentina

Corradini, Paolo

Russo, Pierluigi
License Information

Text and Data Mining valid from 2023-03-13

Version of Record valid from 2023-03-13
More Information

Article History

Received: 18 February 2023

Accepted: 6 March 2023

First Online: 13 March 2023

Declarations

:

: MB received honoraria from Novartis, BMS/Celgene, Pfizer, and Incyte. All the other authors have no conflict of interest.

Document is current

Any future updates will be listed below